Med Pediatr Oncol 1991;19(3):199-203

Effectiveness and toxicity of cisplatin and doxorubicin (PLADO) in childhoo
hepatoblastoma and hepatocellular carcinoma: a SIOP pilot study

Ninane J, Perilongo G, Stalens JP, Guglielmi M, Otte JB, Mancini A
Department of Pediatric Hematology and Oncology, Cliniques Universitaires St.
Luc, Brussels, Belgium
Abstract
Sixteen children, aged 16 days to 13 years with hepatoblastoma (HB) (13
patients) or hepatocellular carcinoma (HCC) (3 patients), were given a total of
89 courses of cisplatin and doxorubicin (PLADO) as IV continuous infusion. All
tumors were confined to the liver except for 1 hepatoblastoma patient with
pulmonary metastases at presentation. Tumor response to PLADO was evaluable in
10 children (8 HB, 2 HCC) treated with preoperative chemotherapy and in another
2 HB patients treated when they developed pulmonary metastases after initial
treatment with surgery alone. There were 2 complete responses (2 HB with
pulmonary recurrences), 7 very good partial responses (6 HB and 1 HCC), 2
partial responses (1 HB, 1 HCC), and 1 stable disease (HB). The last patient
underwent orthotopic liver transplantation whereas all the other patients had
their tumor completely excised at delayed surgery. Documented toxicity was BM
depression (16 patients), infection (11), vomiting (11), mucositis (3), hearing
loss (1), and cardiotoxicity (1). These data indicate that PLADO in continuous
infusion is effective in the treatment of malignant epithelial liver tumors with
acceptable toxicity